The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

San Francisco 49ers players spent the evening celebrating with local families, sharing Team Store shopping, fun games, and a ...

McCormick played a key role passing Gov. Bill Haslam's Tennessee Promise bill, which offers two-year degrees tuition-free to every Tennessee student.

A local man is using what time he has left to to raise awareness about the financial and emotional toll A-L-S, also known as Lou Gehrig’s disease, has on famili ...

By integrating world-class research with multidisciplinary clinical care and family-centered programs under one roof, the Center for Brain Health represents a new model for future-focused neurological ...

ZURICH, Switzerland, Dec. 5, 2025 /PRNewswire/ -- AL-S Pharma, a clinical-stage biotech company dedicated to the development of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS) today ...

LOS ANGELES — A doctor who pleaded guilty to selling ketamine to Matthew Perry was sentenced to 2½ years in prison on ...

Months after Eric Dane shared his ALS diagnosis, the Grey's Anatomy star detailed why he decided to be an advocate for the ...

The ALS Association is awarding $2.14 million in grants to help clinics across the U.S. strengthen multidisciplinary care for ALS patients.

“Grey’s Anatomy” heartthrob Eric Dane appeared on another medical drama on Monday, this time playing a patient. The 53-year-old actor, who played Dr. Mark Sloan aka “McSteamy” on the Shonda Rhimes ...

The medical drama’s showrunner, Michael Grassi, said the experience of making the episode with Dane would impact him for the rest of his life: “Everybody really stepped up in such a beautiful way.” By ...

Funding from the Hugh and Herbert Hoffman ALS Impact Fund will support eligible clinics nationwide and expand access to life-extending ALS care The $2.14 million in grants are made possible through ...